Topica Pharmaceuticals, Inc. is a privately held, clinical-stage specialty pharmaceutical company focused exclusively on developing the first highly effective, safe and convenient topical treatment for onychomycosis, or fungal infections of the toenail and nail bed. Driven by the significant unmet need of the onychomycosis market, our mission is to advance a best-in-class therapeutic that revolutionizes treatment of the disease.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 10/01/11 | Series B | 27M | Third Rock Ventures, Prospect Venture Partners, Yasuda Enterprise Development Corp | Unknown |
People
Norifumi Nakamura (SVP)
Joseph Golemme (CFO)
Greg Vontz (President, CEO)
View more details about the people at Topica Pharmaceuticals
News
Public biotech firms Cadence, Affymax draw $128M from bargain-hunting VCs
February 18, 2009 5:56 pm
Much has been written about how the IPO market froze out biotech companies in 2008, but it looks like times… Continue reading ⟩
Anacor takes $50M to treat fungal infections
January 7, 2009 9:48 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Anacor Pharmaceuticals, a Palo Alto, Calif. firm working on topical… Continue reading ⟩
GangaGen cultures $5.4M to treat bacterial infections
November 26, 2008 12:48 am
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Biotech firm GangaGen, based in Palo Alto, Calif., brought in $5.4 million… Continue reading ⟩